|
|
David Ralph, MBA, Ph.D., has more than two decades of project management
and commercial development expertise in diagnostic product development,
cancer biology, cancer genetics, infectious diseases and microbial ecology. He
has overseen the successful development of numerous molecular assays for
mutation detection, large scale genotyping of humans and identification of
pathogens. Dr. Ralph has also been either the Principal Investigator or an
integral member of teams that have commercialized ELISA, IHC and
immunocytochemical assays for the clinical management of a wide array of
cancers. In addition, Dr. Ralph has extensive experience writing invention
disclosures and patent applications and evaluating intellectual property. He
has served on NIH-NCI SBIR grant review committees evaluating the
commercial feasibility of early-stage technologies. In addition, he has a
successful track record of developing business and product development
strategies for the attainment of extramural funding from private equity
investors. Dr. Ralph received his Ph.D. in 1986 from The Ohio State University
interdisciplinary program in molecular, cellular and developmental biology. Dr.
Ralph completed postdoctoral training fellowships at the Columbia University
medical school and at the Memorial Sloan-Kettering Cancer Center. He then
worked at the California Institute for Biological Research (CIBR), a not for
profit affiliate of Strategene Incorporated, where he help develop differential
display PCR as a tool to examine differential gene expression. Also while at
CIBR, Dr. Ralph pioneered early applications of PCR for the identification and
discrimination of various pathogens. In 1994, Dr. Ralph joined UroCor as head
of their gene discovery group and left Urocor in 2000 as their Director of
Diagnostic Product Development. While at UroCor, Dr. Ralph acted as the lead
scientist responsible for evaluation and/or clinical validation of new diagnostic
products and in licensing opportunities. Since 2000, Dr. Ralph has acted as the
Chief Scientific Officer for a biotechnology start up and has directed
commercialization of molecular based products employing bioinformatics to aid
clinicians in the management of patients with breast cancer and other complex
diseases.
|
|
